## TECH: Bio-Techne Corp - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.83 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-5.4% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($56.57)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Bio-Techne Announces Expanded Launch Of Next-Generation Leo System**
- Source: Nasdaq | 20251209T120903 | Somewhat-Bullish | Relevance: 99%
- Bio-Techne Corp. (TECH) has announced the expanded launch and first shipment of its next-generation Leo System, aiming to set new standards in protein analysis. The system, powered by Simple Western Technology, features dual-channel fluorescence and chemiluminescence detection, promising enhanced data throughput and efficiency for researchers. This innovation is expected to accelerate critical discoveries and streamline development timelines.

**2. Bio-Techne Launches the Enhanced Leo System Delivering Advanced Multiplexing and High-Throughput Protein Analysis**
- Source: Investing News Network | 20251209T120903 | Bullish | Relevance: 99%
-  Bio-Techne Corporation has launched its enhanced Leo System, powered by Simple Western Technology, which introduces dual-channel fluorescence detection alongside chemiluminescence for advanced protein analysis. This system offers expanded multiplexing capabilities, enabling researchers to quantify multiple targets simultaneously and process up to 100 capillaries within three hours. The new Leo System aims to provide unmatched precision and efficiency for clinical research and drug discovery, supporting 21 CFR Part 11 compliance.

**3. Bio-Techne (NASDAQ: TECH) debuts Leo system with dual-channel fluorescence**
- Source: Stock Titan | 20251209T113222 | Somewhat-Bullish | Relevance: 98%
-  Bio-Techne (NASDAQ: TECH) has launched its enhanced Leo System, an upgraded Simple Western platform. This system integrates chemiluminescence with dual-channel near-infrared and infrared fluorescence, significantly expanding its multiplexing capabilities for protein analysis. Key features include the ability to quantify up to 24 targets per sample, process 100 capillaries in three hours with reported 5â€“6% variability, and support 21 CFR Part 11 compliance.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Argus Research | $68 | $65 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Argus Research | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 3 ($0.43M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.5% (-2.7%)
- Blackrock Inc.: 7.6% (-2.3%)
- Morgan Stanley: 4.7% (+10.0%)
- State Street Corpora: 3.7% (-1.8%)
- Wellington Managemen: 3.3% (+349.8%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-5.4% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.83 indicates undervaluation relative to growth. Forward P/E 27.7x stretched relative to 11% growth. Balance sheet: strong liquidity (4.2x), low leverage (D/E 0.29). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.5B |
| Beta | 1.46 |
| 52W Range | $46.01 - $79.28 |
| Short Interest | 6.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.83 |
| Forward P/E | 27.7 |
| Current P/E | 30.7 |
| YoY Growth | 10.9% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.9% to -3.5% (-5.4% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.5pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). RSI neutral at 48.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.50% (CS: 27) | Weak |
| RSI_14 | 48.4 | Neutral |
| MACD Histogram | -0.37 | Bearish |
| vs SMA20 | 0.989x | Below |
| vs SMA50 | 0.991x | Below |
| vs SMA200 | 1.098x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $60.83
- **Stop Loss:** $56.57 (7.0% risk)
- **Target:** $69.35 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 117
- **Position Value:** $7,117.11
- **Portfolio %:** 7.12%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-02-09 (Est: $0.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.42 | $0.42 | -0.4% |
| 2025Q2 | $0.50 | $0.53 | +5.8% |
| 2025Q1 | $0.51 | $0.56 | +10.4% |
| 2024Q4 | $0.39 | $0.42 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*